Securities Code: 300796 Securities Abbreviation: Beisimei Announcement Number: 2026-009 Shaoxing Beisimei Chemical Co., Ltd. Announcement on Changing the Use of Some Raised Funds for Permanent Supplementation of Working Capital
The company and all members of the board of directors guarantee the content of the information disclosed is true, accurate, and complete, and there are no false records, misleading statements, or major omissions.
Shaoxing Beisimei Chemical Co., Ltd. (hereinafter referred to as the "Company") held the first meeting of the Fourth Board of Directors Strategic Committee in 2026 on March 30, 2026, and the second meeting of the Fourth Board of Directors Audit Committee in 2026 on March 30, 2026. On March 31, 2026, the fourteenth meeting of the Fourth Board of Directors was held, and the "Proposal on Changing the Use of Some Raised Funds for Permanent Supplementation of Working Capital" was deliberated and approved. It was agreed that 68 million RMB of raised funds from the "Annual Output of 6,000 Tons of Dichlorovinyl Methyl Ether Technical Improvement Project" would be permanently supplemented to working capital. The sponsor, Zhongtai Securities Co., Ltd. (hereinafter referred to as the "Sponsor"), has issued a clear no-objection review opinion on this matter.
In accordance with the "Supervision Regulations on Raised Funds of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 2 - Standardized Operation of GEM Listed Companies," and other relevant regulations, this matter still needs to be submitted for review by the first extraordinary general meeting of shareholders of the Company in 2026. The relevant matters are hereby announced as follows:
I. Overview of the Change in the Use of Raised Funds for Initial Public Offering Investment Projects
(I) Basic Situation of Raised Funds from the Initial Public Offering in 2019
Shaoxing Beisimei Chemical Co., Ltd. (hereinafter referred to as "Beisimei" or the "Company"), with the approval of the China Securities Regulatory Commission's Issuance Letter [2019] No. 1783, publicly issued 30.3 million shares of RMB ordinary shares (A shares) in November 2019, with an issue price of 14.25 RMB per share. The total amount of raised funds was 431.775 million RMB. After deducting issuance expenses of 38.7974 million RMB according to relevant regulations, the net amount of raised funds was 392.9776 million RMB. The raised funds were received in November 2019. The receipt of these funds was verified by the Capital Verification Report [2019] No. 7999 issued by Rongcheng Certified Public Accountants. The company adopted a special account management for the raised funds.
(II) Use and Management of Raised Funds from the Initial Public Offering
As of December 31, 2025, the usage of raised funds for investment projects from the Company's initial public offering is as follows: